US FDA approves Bydureon BCise for type-2 diabetes
23 October 2017 07:00 BST US FDA APPROVES NEW EASY-TO-USE, ONCE-WEEKLY BYDUREON BCISE INJECTABLE MEDICINE FOR PATIENTS WITH TYPE-2 DIABETES New formulation of once-weekly exenatide in an improved device provides significant HbA1c reduction with added benefit of weight loss AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Bydureon BCise (exenatide extended-release) injectable suspension, a new formulation of Bydureon in an improved once-weekly, single-dose autoinjector device for adults with type-2 diabetes whose blood sugar remains